phase III

Data demonstrate real-world benefits of fluocinolone acetonide implantReal-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
Ohr plans Phase III trials on squalamine eye drops for wet AMDOhr Pharmaceutical recently announced details of the planned Phase III registration trials for squalamine eye drops (OHR-102) in the treatment of wet age-related macular degeneration (AMD), which are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent "end of Phase II" meeting.
B+L initiates Phase III program for glaucoma drug candidate licensed from NicoxBausch + Lomb has started its Phase III clinical program of latanoprostene bunod licensed by Nicox S.A. to B+L. B+L’s drug candidate is meant to reduce IOP in patients with elevated IOP due to glaucoma or ocular hypertension.